Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

- PMLiVE

Innovative Trials featuring in a Clinical Trials Arena article

Leanne Keem, Head of Operations and Client Relationship at Innovative Trials, featured in a recent article.

Innovative Trials

- PMLiVE

Closing The Gaps in Patient-Centricity in Cancer Care

Highlights from the Medscape Education full panel discussion during this year's #ESMO22.

Medscape Education

Full Panel Discussion: Closing The Gaps In Patient-Centricity

On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

Medscape Education

- PMLiVE

A day late and a dollar short

By Rohit Khanna

EVOKE STRENGTHENS LEADERSHIP TEAM IN EUROPE TO DELIVER MORE INTEGRATED CLIENT SOLUTIONS

*Corrina Safeio, promoted to Group Managing Director taking on responsibility for Evoke London and Evoke Mind+Matter *Lee Wales, promoted to Deputy Managing Director at Evoke Mind+Matter UK *Holly Ford, promoted...

Inizio

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

- PMLiVE

Kite and Refuge Biotechnologies join to develop potential treatments for blood cancer

The agreement bolsters Kite’s expertise in synthetic biology for oncology

- PMLiVE

ICR research shows blood tests could help guide the treatment for children’s cancer

Using liquid biopsies to monitor patients could determine how well treatment is working

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

GSK’s shingles vaccine demonstrates at least ten-year efficacy in long-term study

ZOSTER-049 follows participants from two phase 3 trials for an additional six years

Closing the Gaps in Telehealth

Anthony Capone, President of DocGo, shares how his company uses last-mile mobile health services and integrated medical transportation solutions to make healthcare more accessible for everyone, including underserved populations.

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links